Abstract:The splice variants specific protein expression in tumor cells presents promising targets for cancer therapy. The concept is supported by the recent introduction of the splice variant-specific antibody against FGFR2 IIIb (FGFR2b) in gastric cancer. Indeed, signaling of the two FGFR2 splice variants FGFR2b and FGFR2 IIIc (FGFR2c), whose expression is mutually exclusive on a cellular level, is mediated by different ligands and distinct downstream responses that can contribute to many aspects of tumorigenesis. Our study aimed to characterize the expression FGFR2b and 2c in non-malignant lung and non-small cell lung cancer (NSCLC) tissue and relate splice variant-specific expression to the histological and molecular background of cancer and its clinical impact.FGFR2b/FGFR2c isoforms expression was determined in RNA-seq data from 180 NSCLC patients and 19 tissues from normal lung (patient-matched). Cell-type specific expression and pan-cancer analysis of FGFR2 were explored using a public database, including DBTSS (NSCLC: 26, normal lung epithelium: 1, normal lung fibroblast 1) and CCLE (Total: 1019, NSCLC: 131), GTEx (normal lung tissue: 578) and HPA (scRNAseq for lung).Our results confirm a cell-specific expression in normal cells with dominance of FGFR2b in epithelial cells and FGFR2c in mesenchymal cells. In normal lung tissue, the FGFR2b variant showed high abundance. Pan-cancer analysis revealed FGFR2c dominant cancers (e.g., CNS tumors, kidney, liver) as well as FGFR2b dominant cancer types (e.g., breast, colon, lung cancer). The RNAseq data from our NSCLC cohort showed a chief expression of FGFR2b in 116 cases (64%), FGFR2c in 31 cases (17%), and a mixed FGFR2c/FGFR2b transcriptomics (18%). The ratio of FGFR2b/FGFR2c as a metric for splice variant dominance was associated with squamous histology, higher stage, and KRAS mutations. Differential gene expression analysis of cancer tissue and cell lines revealed an association of the splice variant FGFR2c to epithelial-mesenchymal transition (EMT) and the regulation of genes (ZEP1, ERSP1, CDH1) involved in the TGF-beta signal pathway. Finally, the ratio of FGFR2b/FGFR2c demonstrated a strong association with overall survival in NSCLC patients with the FGFR2c variant as unfavorable predictors (High vs low ratio, p = 0.01). Our study indicates cell-specific splice variant expression in non-malignant and malignant cells. The prognostic unfavorable impact of the FGFR2c variant on NSCLC patient survival might be explained by its association with TGF signaling and EMT. The observed clinical and biological difference between FGFR2b and FGFR2c dominated cancers gives further rationale to exploit splice variants as therapeutical targets. Citation Format: Hui Yu, Masafumi Horie, Amanda Lindberg, Max Backman, Neda Hekmati, Johanna Mattsson, Naoya Miyashita, Hans Brunnström, Fredrik Ponten, Akira Saito, Carina Strell, Patrick Micke. FGFR2 splice variant as a cell fate adjudicator determines clinical outcomes in non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 208.

Exon III Splicing of FGF Receptor 1 is Modulated by Growth Factors and Cyclin D1

Exon Iii Splicing of Fibroblast Growth Factor Receptor 1 is Modulated by Growth Factors and Cyclin D1

Igfbp-Rp1, A Potential Molecule Associated with Colon Cancer Differentiation

The Role of Human Fibroblast Growth Factor Receptor 1-ⅲB Isoform in Pancreatic Cancer Cells

Interactions of Pancreatic Cancer and Stellate Cells Are Mediated by Fgfr1-Iii Isoform Expression

FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells

[The Role of Human Fibroblast Growth Factor Receptor 1-Iiib Isoform in Proliferation of Pancreatic Ductal Cells and Its Effects to Mitogen-Activated Protein Kinase].

Regulation of pancreatic cancer cells by fibroblast growth factor receptor-1

Data from FGFR2 Isoforms Support Epithelial–Stromal Interactions in Thyroid Cancer Progression

Lower FGFR2 mRNA Expression and Higher Levels of FGFR2 IIIc in HER2-Positive Breast Cancer

Alternatively Spliced FGFR-1 Isoforms Differentially Modulate Endothelial Cell Activation of C-Yes

Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response

The Nonsense-Mediated Decay Pathway and Mutually Exclusive Expression of Alternatively Spliced FGFR2IIIb and -Iiic Mrnas.

EIF3B promotes cancer progression in pancreatic cancer

Direct Regulation of Alternative Splicing by SMAD3 Through PCBP1 is Essential to the Tumor-Promoting Role of TGF-β

Regulation of Hair Follicle Growth and Development by Different Alternative Spliceosomes of FGF5 in Rabbits

Cellular Stress Response 1 Down-Regulates the Expression of Epidermal Growth Factor Receptor and Platelet-Derived Growth Factor Receptor Through Inactivation of Splicing Factor 3A3

The Breast Cancer Susceptibility Gene Product Fibroblast Growth Factor Receptor 2 Serves As a Scaffold for Regulation of NF-κB Signaling.

Knockdown EIF3C Suppresses Cell Proliferation and Increases Apoptosis in Pancreatic Cancer Cell

Abstract 208: FGFR2 splice variant as a cell fate adjudicator determines clinical outcomes in non-small cell lung cancer

Retracted: The Breast Cancer Susceptibility Gene Product Fibroblast Growth Factor Receptor 2 Serves As A Scaffold For Regulation Of Nf-Kappa B Signaling (Retracted Article. See Vol. 38, 2018)